Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04332653
Title NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors NeoImmuneTech
Indications

lung non-small cell carcinoma

triple-receptor negative breast cancer

pancreatic cancer

lung small cell carcinoma

Advanced Solid Tumor

colorectal cancer

Therapies

NT-I7 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Moffit Cancer Center Recruiting Tampa Florida 33612 United States Details
Barbara Ann Karmanos Cancer Institute Recruiting Detroit Michigan 48201 United States Details
Washington University School of Medicine in St. Louis Recruiting Saint Louis Missouri 63110 United States Details
Duke University Medical Center Recruiting Durham North Carolina 27710 United States Details
Fox Chase Cancer Center Recruiting Philadelphia Pennsylvania 19111 United States Details
Sarah Cannon Research Institute Recruiting Nashville Tennessee 37211 United States Details
Mary Crowley Cancer Research Active, not recruiting Dallas Texas 75230 United States Details
MD Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field